Blevins Molly S, Chin Steven, Wang Jenny, Famili Amin, Cadang Lance, Wei Bingchuan, Zhang Kelly
Synthetic Molecule Analytical Chemistry, Genentech Inc., South San Francisco, California 94080, United States.
Anal Chem. 2025 Feb 18;97(6):3554-3562. doi: 10.1021/acs.analchem.4c05968. Epub 2025 Jan 20.
Accurate characterization of therapeutic RNA, including purity and identity, is critical in drug discovery and development. Here, we utilize denaturing and non-denaturing chromatography for the analysis of ∼25 kDa divalent small interfering RNA (di-siRNA), which comprises a complex 2:1 triplex structure. Ion pair reversed-phase (IPRP) liquid chromatography (LC) experiments with UV absorbance and mass spectrometry (MS) showcase a single denaturing LC method for identity confirmation, impurity profiling, and sequencing with automated MS data interpretation. IPRP, size exclusion chromatography (SEC), and melting temperature () experiments showcase the need for consideration of chromatographic conditions in evaluating noncovalent siRNA structures─here, low-temperature IPRP experiments (generally considered "non-denaturing") indicate denaturation of the noncovalent complex for certain di-siRNA sequences, while SEC data indicate that di-siRNA aggregation can be vastly underestimated due to sample dilution prior to LC experiments. Furthermore, SEC data critically show the propensity of denatured di-siRNA samples to renature under SEC mobile phase conditions upon exposure to high ionic/salt solutions, corroborated by experiments. This work highlights the need for consideration of the noncovalent nature of certain RNA therapeutics during sample preparation, method development, and analytical characterization and the often sequence-specific strength of complex formation, which may significantly affect analytical results obtained for such molecules. Attention to the highly dynamic nature of the duplex RNA structure, which is heavily influenced by its environment, must be considered during analytical method development.
对治疗性RNA进行准确表征,包括纯度和身份鉴定,在药物发现和开发中至关重要。在此,我们利用变性和非变性色谱法分析约25 kDa的二价小干扰RNA(di-siRNA),其具有复杂的2:1三链体结构。采用紫外吸收和质谱(MS)的离子对反相(IPRP)液相色谱(LC)实验展示了一种单一的变性LC方法,用于身份确认、杂质分析和测序,并具有自动MS数据解释功能。IPRP、尺寸排阻色谱(SEC)和熔解温度()实验表明,在评估非共价siRNA结构时需要考虑色谱条件——在此,低温IPRP实验(通常被认为是“非变性”)表明某些di-siRNA序列的非共价复合物会变性,而SEC数据表明,由于LC实验前样品稀释,di-siRNA聚集可能被大大低估。此外,SEC数据关键地表明,变性的di-siRNA样品在暴露于高离子/盐溶液时,在SEC流动相条件下有重新复性的倾向,实验证实了这一点。这项工作强调了在样品制备、方法开发和分析表征过程中需要考虑某些RNA治疗药物的非共价性质,以及复合物形成通常具有的序列特异性强度,这可能会显著影响此类分子的分析结果。在分析方法开发过程中,必须考虑双链RNA结构高度动态的性质,其受到环境的严重影响。